EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY 4.0

A randomized phase 1b/2 trial of ABBV‐916 in adults with early Alzheimer's disease

Shau Yu Lynch iD, Yamin Wang, Deli Wang, Sagar S Bachhav, Hao Xiong, Joey Boiser, Edwin Stage, Anthony W Bannon, Ole Graff, Hana Florian

Alzheimer's & Dementia · 2026

DOI: 10.1002/alz.71715 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Shau Yu Lynch und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Development, AbbVie Inc., North Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Inc., AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION ABBV‐916, an anti‐amyloid immunotherapy, was evaluated in patients with early Alzheimer's disease (AD). METHODS This phase 1b/2, double‐blind, placebo‐controlled study consisted of two stages: multiple ascending dose (Stage A) and dose expansion (Stage B). In Stage A, patients were randomized to one of six planned cohorts to receive intravenous ABBV‐916 (10 mg to 3000 mg) or placebo monthly through week 24. Assessments included amyloid PET, blood‐based biomarkers, pharmacokinetics (PK), and safety. Dose selection for Stage B was to be based on results from Stage A. RESULTS One hundred six patients were randomized to ABBV‐916 or placebo. The 3000 mg dose was reduced to 2000 mg and subsequently to 900 mg after safety review. Dose‐proportional PK were observed, and amyloid reduction was observed over 24 weeks at doses ≥300 mg. Most adverse events were non‐serious amyloid‐related imaging abnormalities. The program ended before dose expansion due to business considerations. DISCUSSION Amyloid clearance rate and safety of ABBV‐916 were generally comparable to approved anti‐amyloid AD therapies. CLINICAL TRIAL REGISTRATION INFORMATION NCT05291234

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAntibodies, Monoclonal, HumanizedHumansFemaleMaleDouble-Blind MethodAgedAmyloid beta-PeptidesPositron-Emission TomographyDose-Response Relationship, DrugMiddle AgedAged, 80 and overTreatment OutcomeBiomarkers

Stichwörter der Autor:innen

AβpE3amyloidamyloid beta 42/40 (Aβ42/Aβ40)amyloid‐related imaging abnormality (ARIA)apolipoprotein E ε4 allele (APOE ε4)clinical trialglial fibrillary acidic protein (GFAP)multiple ascending dosepharmacokineticsphase 1bpositron emission tomography (PET)p‐tau217

Substanzen

Amyloid beta-PeptidesAntibodies, Monoclonal, HumanizedBiomarkers

Autor:innen und Institutionen

  • Clinical Development, AbbVie Inc., North Chicago, Illinois, USA.
  • Statistics, AbbVie Inc., North Chicago, Illinois, USA.
  • Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.
  • Global Patient Safety, AbbVie Inc., North Chicago, Illinois, USA.
  • Discovery Science, AbbVie Inc., North Chicago, Illinois, USA.
  • Precision Medicine, AbbVie Inc., North Chicago, Illinois, USA.

ORCID-Profile: Shau Yu Lynch

Förderung

  • AbbVie Inc.
  • AbbVie

Zitieren

APA

Lynch, S. Y., Wang, Y., Wang, D., Bachhav, S. S., Xiong, H., Boiser, J., Stage, E., Bannon, A. W., Graff, O., & Florian, H. (2026). A randomized phase 1b/2 trial of ABBV‐916 in adults with early Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71715

Vancouver

Lynch SY, Wang Y, Wang D, Bachhav SS, Xiong H, Boiser J, et al. A randomized phase 1b/2 trial of ABBV‐916 in adults with early Alzheimer's disease. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71715

BibTeX
@article{Lynch2026,
  author = {Lynch, Shau Yu and Wang, Yamin and Wang, Deli and Bachhav, Sagar S and Xiong, Hao and Boiser, Joey and Stage, Edwin and Bannon, Anthony W and Graff, Ole and Florian, Hana},
  title = {A randomized phase 1b/2 trial of ABBV‐916 in adults with early Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  doi = {10.1002/alz.71715}
}
Kostenlos starten →